Merck: Buy for 2026 With Patience—Keytruda Strength Is the Engine, Guidance Is the Brake
Merck (MRK) is a pragmatic buy into 2026. The stock trades at roughly a mid-teens P/E, produces strong free cash flow ($13.05B), and still benefits from Keytruda momentum and an expanding animal health business. Near-term guidance that missed Street estimates and binary clinical readouts create a time-sensitive window—the fundamentals argue for acc…